Nyemissioner.se has conducted an interview with Fredrik Rickman, CEO of Prostatype Genomics. In the article, published on the Nyemissioner.se news page, Fredrik Rickman discusses new long-term data demonstrating significant added value for the company’s genetic test, Prostatype®, compared to the NCCN’s established risk classification system. He also addresses the status of the company’s ongoing process with Medicare regarding reimbursement in the US; a working meeting with Medicare is scheduled for early November.
The company will update the market when further relevant information regarding the process becomes available.
The full article (in Swedish) can be read at the following link:
https://nyemissioner.se/nyheter/prostatype-visar-starka-langtidsdata-medicare-processen-gar-vidare/
For more information about the Company, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 (0)73 049 77 01
E-mail: fredrik.rickman@prostatypegenomics.com
Certified Adviser
Tapper Partners AB
Telephone: +46 (0)70 44 010 98
E-mail: ca@tapperpartners.se
About Prostatype Genomics
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.